A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease

被引:46
|
作者
Leiper, K
Woolner, J
Mullan, MMC
Parker, T
van der Vliet, M
Fear, S
Rhodes, JM
Hunter, JO
机构
[1] Univ Liverpool, Dept Med, Gastroenterol Res Grp, Liverpool L69 3GA, Merseyside, England
[2] Addenbrookes Hosp, Dept Gastroenterol, Cambridge CB2 2QQ, England
[3] Int Ctr Lung Canc Res, Liverpool, Merseyside, England
关键词
Crohn's disease therapy; polymeric feeds; dietary fat;
D O I
10.1136/gut.49.6.790
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background-Polymeric feeds have shown variable efficacy in active Crohn's disease (CD) with remission rates from 36% to 82%. Meta-analyses of elemental, peptide, and whole protein feeds have shown a strong negative correlation between remission rate in CD and the long chain triglyceride (LCT) content of the feed. We performed a randomised controlled double blind trial in patients with active CD comparing two single whole protein feeds with LCT supplying 5% or 30% of the total energy. Methods-Fifty four patients with active CD (Crohn's disease activity index (CDAI) > 200, serum C reactive protein (CRP) 10 mg/1) were randomised to a high or low LCT feed for three weeks. The total amount of energy supplied by fat was identical in the two feeds. Remission was defined as a CDAI less than or equal to 150 and response as a fall in CDAI of greater than or equal to 70 or a CRP < 10 mg/l. Results-Overall remission rate by intention to treat was 26% for the low LCT feed and 33% for the high LCT feed (p=0.38). Response was achieved in 33% with the low LCT and in 52% with the high LCT feed (p=0.27). CRP < 10 mg/l was achieved in 30% in the low LCT and 33% in the high LCT group (p=0.99). Thirty nine per cent (21/54) of patients withdrew before three weeks because of inability to tolerate the diet. Excluding patients unable to tolerate the diet, remission rates were 46% for low LCT and 45% for high LCT (p=0.99). Discussion-This trial has shown no difference in the effect of low and high LCT whole protein feeds in active CD. The previously reported correlation between LCT content of diet and response in active CD is unlikely to be due to LCT itself and may be due to some other component of high LCT feeds.
引用
收藏
页码:790 / 794
页数:5
相关论文
共 50 条
  • [31] Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial
    Ponsioen, Cyriel Y.
    de Groof, E. Joline
    Eshuis, Emma J.
    Gardenbroek, Tjibbe J.
    Bossuyt, Patrick M. M.
    Hart, Ailsa
    Warusavitarne, Janindra
    Buskens, Christianne J.
    van Bodegraven, Ad A.
    Brink, Menno A.
    Consten, Esther C. J.
    van Wagensveld, Bart A.
    Rijk, Marno C. M.
    Crolla, Rogier M. P. H.
    Noomen, Casper G.
    Houdijk, Alexander P. J.
    Mallant, Rosalie C.
    Boom, Maarten
    Marsman, Willem A.
    Stockmann, Hein B.
    Mol, Bregje
    de Groof, A. Jeroen
    Stokkers, Pieter C.
    D'Haens, Geert R.
    Bemelman, Willem A.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (11): : 785 - 792
  • [32] Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial
    Escher, JC
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (01) : 47 - 54
  • [33] Crohn's disease strictures respond to adalimumab drug treatment: Long term (4.5 years) results of the STRIDENT randomised controlled trial
    Lovett, Grace
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 230 - 231
  • [34] Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
    Van Assche, Gert
    Vermeire, Severine
    Ballet, Vera
    Gabriels, Frederik
    Noman, Maja
    D'Haens, Geert
    Claessens, Christophe
    Humblet, Evelien
    Casteele, Niels Vande
    Gils, Ann
    Rutgeerts, Paul
    GUT, 2012, 61 (02) : 229 - 234
  • [35] COMBINED IMPACT AND RESISTANCE TRAINING IN ADULTS WITH STABLE CROHN'S DISEASE: PROTECT RANDOMISED CONTROLLED TRIAL
    Jones, Katherine
    Baker, Katherine
    Speight, Richard A.
    Thompson, Nick P.
    Tew, Garry
    GUT, 2021, 70 : A9 - A9
  • [36] A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn's disease
    Hill, L.
    Popov, J.
    Hartung, E.
    Moshkovich, M.
    Figueiredo, M.
    Pai, N.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S447 - S447
  • [37] Randomised open-label controlled trial of ciprofloxacin/doxycycline/hydroxychloroquine combination compared with standard budesonide in active Crohn's disease (APRICOT)
    Rhodes, J. M.
    Subramanian, S.
    Flanagan, P.
    Horgan, G.
    Martin, K.
    Mansfield, J.
    Parkes, M.
    Hart, A.
    Dallal, H.
    Iqbal, T.
    Butterworth, J.
    Culshaw, K.
    Probert, C.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S487 - S487
  • [38] Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial
    Allez, Matthieu
    Skolnick, Brett E.
    Wisniewska-Jarosinska, Maria
    Petryka, Robert
    Overgaard, Rune Viig
    GUT, 2017, 66 (11) : 1918 - 1925
  • [39] Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial
    Levine, Arie
    Kori, Michal
    Kierkus, Jarek
    Boneh, Rotem Sigall
    Sladek, Malgorzata
    Escher, Johanna C.
    Wine, Eytan
    Yerushalmi, Baruch
    Dias, Jorge Amil
    Shaoul, Ron
    Wauters, Gigi Veereman
    Boaz, Mona
    Abitbol, Guila
    Bousvaros, Athos
    Turner, Dan
    GUT, 2019, 68 (02) : 239 - 247
  • [40] Elimination diets in the treatment of mildly active Crohn's disease - Results of a randomized controlled trial
    Danel, Ilana
    Levi, Zohar
    Fraser, Abigail
    Hadad, Bracha
    Niv, Yaron
    Fraser, Gerald
    GASTROENTEROLOGY, 2007, 132 (04) : A506 - A507